Compare · ILMN vs NEUE
ILMN vs NEUE
Side-by-side comparison of Illumina Inc. (ILMN) and NeueHealth Inc. (NEUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and NEUE operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $23.91B.
- Over the past year, ILMN is up 86.1% and NEUE is down 1.2% - ILMN leads by 87.3 points.
- ILMN has hit the wire 22 times in the past 4 weeks while NEUE has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for NEUE).
- Company
- Illumina Inc.
- NeueHealth Inc.
- Price
- $158.13-2.55%
- $6.84+2.09%
- Market cap
- $23.91B
- -
- 1M return
- +14.02%
- +2.09%
- 1Y return
- +86.08%
- -1.23%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- 2021
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest NEUE
- Chief Financial Officer Matushak Jay returned 40,431 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by NeueHealth Inc.
- Large owner Bessemer Venture Partners Ix L.P. returned 999,218 shares to the company (SEC Form 4)
- Director Kraus Stephen returned 16,443 shares to the company, closing all direct ownership in the company (SEC Form 4)
- GC & Corporate Secretary Craig Jeffery Michael returned 20,103 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, Consumer Care Orozco Tomas returned 29,325 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sheehy Robert J returned 265,945 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Adkins Kedrick D Jr returned 16,443 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Kadre Manuel returned 33,505 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Slavitt Andrew M returned 107,809 shares to the company, closing all direct ownership in the company (SEC Form 4)